Exelixis (EXEL) Current Deferred Revenue (2010 - 2023)
Exelixis (EXEL) recorded quarterly Current Deferred Revenue of $13.5 million in Q2 2023, up 1.21% quarter-over-quarter from $13.4 million in Q1 2023, and down 8.13% on a YoY basis from $14.7 million in Q2 2022.
Exelixis (EXEL) Current Deferred Revenue (2010 - 2023) Analysis & Trends
Exelixis' Current Deferred Revenue history runs 14 years deep, the most recent figure standing at $13.5 million for Q2 2023.
- In Q2 2023, Current Deferred Revenue fell 8.13% year-over-year to $13.5 million; the TTM figure through Jun 2023 stood at $13.5 million (down 8.13% YoY), while the FY2022 annual figure was $14.1 million, down 15.0% from the prior year.
- Current Deferred Revenue was $13.5 million for Q2 2023 at Exelixis, up from $13.4 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $19.0 million in Q2 2021 to a low of $321000.0 in Q2 2019.
- Historically, Current Deferred Revenue has averaged $12.1 million across 5 years, with a median of $13.8 million in 2022.
- The sharpest annual moves came in 2019 and 2020: Current Deferred Revenue sank 94.6% in 2019, then soared 4977.88% in 2020.
- A 5-year view of Current Deferred Revenue shows it stood at $8.2 million in 2019, then climbed by 29.27% to $10.6 million in 2020, then jumped by 56.16% to $16.6 million in 2021, then dropped by 15.0% to $14.1 million in 2022, then dropped by 3.87% to $13.5 million in 2023.
- The last three Current Deferred Revenue figures came in at $13.5 million (Q2 2023), $13.4 million (Q1 2023), and $14.1 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13.53 Mn |
| Mar 31, 2023 | 13.36 Mn |
| Dec 30, 2022 | 14.07 Mn |
| Sep 30, 2022 | 13.42 Mn |
| Jul 1, 2022 | 14.72 Mn |
| Apr 1, 2022 | 15.38 Mn |
| Dec 31, 2021 | 16.55 Mn |
| Oct 1, 2021 | 16.98 Mn |
| Jul 2, 2021 | 14.89 Mn |
| Apr 2, 2021 | 18.97 Mn |
| Jan 1, 2021 | 5.55 Mn |
| Oct 2, 2020 | 10.60 Mn |
| Jul 3, 2020 | 16.30 Mn |
| Apr 3, 2020 | 15.40 Mn |
| Jan 3, 2020 | 6.60 Mn |
| Sep 27, 2019 | 8.20 Mn |
| Jun 28, 2019 | 321,000.00 |
| Mar 29, 2019 | 2.38 Mn |
| Dec 28, 2018 | 18.00 Mn |
| Jun 29, 2018 | 5.94 Mn |